Simvastatin and Cyclosporine Interaction

Understanding the Simvastatin and Cyclosporine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Simvastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class and Cyclosporine belongs to the Calcineurin Inhibitor (Immunosuppressant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cyclosporine prevents your body from processing simvastatin correctly, which can cause a dangerous amount of the drug to build up. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Simvastatin has 41 total documented interactions on file in this dataset, and Cyclosporine has 89. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid taking these two drugs together because the combination is unsafe and can cause severe muscle damage. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Simvastatin or Cyclosporine based on a web page, speak with your prescriber or pharmacist before making any change.